首页膀胱肿瘤治疗及预后证据详情

Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis

原文: 2016 年 发布于 Bju International 浏览量:220次

作者: Wu H. R. Wang X. G. Zhang L. Mo N. X. Lv Z.

作者单位: Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. urology2007@126.com. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. cwu2@partners.org. Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. cwu2@partners.org.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1007/s00251-021-01205-w

文献简介

Background: Methylation of the tumor suppressor gene H-cadherin (CDH13) has been reported in many cancers. However, the clinical effect of the CDH13 methylation status of patients with bladder cancer remains to be clarified. Methods: A systematic literature search was performed to identify eligible studies in the PubMed, Embase, EBSCO, CKNI and Wanfang databases. The pooled odds ratio (OR) and the corresponding 95 % confidence interval (95 % CI) was calculated and summarized. Results: Nine eligible studies were included in the present meta-analysis consisting of a total of 1017 bladder cancer patients and 265 non-tumor controls. A significant association was found between CDH13 methylation levels and bladder cancer (OR = 21.71, P < 0.001). The results of subgroup analyses based on sample type suggested that CDH13 methylation was significantly associated with bladder cancer risk in both the tissue and the urine (OR = 53.94, P < 0.001; OR = 7.71, P < 0.001; respectively). A subgroup analysis based on ethnic population showed that the OR value of methylated CDH13 was higher in Asians than in Caucasians (OR = 35.18, P < 0.001; OR = 8.86, P < 0.001; respectively). The relationships between CDH13 methylation and clinicopathological features were also analyzed. A significant association was not observed between CDH13 methylation status and gender (P = 0.053). Our results revealed that CDH13 methylation was significantly associated with high-grade bladder cancer, multiple bladder cancer and muscle invasive bladder cancer (OR = 2.22, P < 0.001; OR = 1.45, P = 0.032; OR = 3.42, P < 0.001; respectively). Conclusion: Our study indicates that CDH13 methylation may play an important role in the carcinogenesis, development and progression of bladder cancer. In addition, CDH13 methylation has the potential to be a useful biomarker for bladder cancer screening in urine samples and to be a prognostic biomarker in the clinic.

热门文献